What is William Blair’s Forecast for KZR Q1 Earnings?

Kezar Life Sciences, Inc. (NASDAQ:KZR) – William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Kezar Life Sciences in a research report issued to clients and investors on Tuesday, March 25th. William Blair analyst M. Phipps anticipates that the company will earn ($2.95) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($4.39) per share. William Blair also issued estimates for Kezar Life Sciences’ Q2 2026 earnings at ($3.03) EPS, Q3 2026 earnings at ($3.10) EPS and Q4 2026 earnings at ($3.16) EPS.

Other research analysts also recently issued reports about the company. Wells Fargo & Company lowered their price target on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 19th. HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd.

Kezar Life Sciences Price Performance

Shares of NASDAQ KZR opened at $4.92 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.65. The business has a 50-day moving average of $6.00 and a 200-day moving average of $6.68. The stock has a market capitalization of $35.90 million, a price-to-earnings ratio of -0.37 and a beta of 0.49. Kezar Life Sciences has a fifty-two week low of $4.90 and a fifty-two week high of $9.27.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, March 25th. The company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.71) by ($0.06).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its holdings in Kezar Life Sciences by 613.8% during the 4th quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock valued at $80,000 after purchasing an additional 10,219 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Kezar Life Sciences in the fourth quarter valued at about $217,000. XTX Topco Ltd lifted its stake in shares of Kezar Life Sciences by 256.1% during the 3rd quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after buying an additional 37,504 shares during the last quarter. BML Capital Management LLC bought a new stake in shares of Kezar Life Sciences during the 4th quarter worth about $327,000. Finally, Shay Capital LLC acquired a new position in Kezar Life Sciences in the 4th quarter valued at about $398,000. 67.90% of the stock is currently owned by institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.